Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification

被引:34
作者
Jia, Shanshan [1 ]
Luo, Hua [2 ]
Liu, Xinkui [1 ]
Fan, Xiaotian [1 ]
Huang, Zhihong [1 ]
Lu, Shan [1 ]
Shen, Liangliang [1 ]
Guo, Siyu [1 ]
Liu, Yingying [1 ]
Wang, Zhenzhong [3 ,4 ]
Cao, Liang [3 ,4 ]
Cao, Zeyu [3 ,4 ]
Zhang, Xinzhuang [3 ,4 ]
Zhou, Wei [1 ]
Zhang, Jingyuan [1 ]
Li, Jialin [1 ]
Wu, Jiarui [1 ]
Xiao, Wei [3 ,4 ]
机构
[1] Beijing Univ Chinese Med, Sch Chinese Mat Medial, Dept Clin Chinese Pharm, 11 North Three Ring East Rd, Beijing 100102, Peoples R China
[2] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China
[3] State Key Lab New Tech Chinese Med Pharmaceut Pro, Lianyungang 222001, Jiangsu, Peoples R China
[4] Key Lab New Tech Res TCM Extract & Purificat, Lianyungang 222047, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Reduning injection; COVID-19; Network pharmacology; SARS-CoV-2; Molecular docking; Western blot; ACUTE LUNG INJURY; TRADITIONAL CHINESE MEDICINE; CYTOKINE STORM; KAPPA-B; TARGETS; INFLAMMATION; PREDICTION; CELLS;
D O I
10.1016/j.jep.2021.113871
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Reduning injection (RDNI) is a patented Traditional Chinese medicine that contains three Chinese herbal medicines, respectively are the dry aboveground part of Artemisia annua L., the flower of Lonicera japonica Thunb., and the fruit Gardenia jasminoides J.Ellis. RDNI has been recommended for treating Coronavirus Disease 2019 (COVID-19) in the ?New Coronavirus Pneumonia Diagnosis and Treatment Plan". Aim of the study: To elucidate and verify the underlying mechanisms of RDNI for the treatment of COVID-19. Methods: This study firstly performed anti-SARS-CoV-2 experiments in Vero E6 cells. Then, network pharmacology combined with molecular docking was adopted to explore the potential mechanisms of RDNI in the treatment for COVID-19. After that, western blot and a cytokine chip were used to validate the predictive results. Results: We concluded that half toxic concentration of drug CC50 (dilution ratio) = 1:1280, CC50 = 2.031 mg crude drugs/mL (0.047 mg solid content/mL) and half effective concentration of drug (EC50) (diluted multiples) = 1:25140.3, EC50 = 103.420 ?g crude drugs/mL (2.405 ?g solid content/mL). We found that RDNI can mainly regulate targets like carbonic anhydrases (CAs), matrix metallopeptidases (MMPs) and pathways like PI3K/AKT, MAPK, Forkhead box O s and T cell receptor signaling pathways to reduce lung damage. We verified that RDNI could effectively inhibit the overexpression of MAPKs, PKC and p65 nuclear factor-?B. The injection could also affect cytokine levels, reduce inflammation and display antipyretic activity. Conclusion: RDNI can regulate ACE2, Mpro and PLP in COVID-19. The underlying mechanisms of RDNI in the treatment for COVID-19 may be related to the modulation of the cytokine levels and inflammation and its antipyretic activity by regulating the expression of MAPKs, PKC and p65 nuclear factor NF-?B.
引用
收藏
页数:15
相关论文
共 77 条
  • [1] Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease Pros and Cons
    Adamson, Rosemary
    Swenson, Erik R.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (07) : 1086 - 1093
  • [2] Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
    Ahmed, Syed Faraz
    Quadeer, Ahmed A.
    McKay, Matthew R.
    [J]. VIRUSES-BASEL, 2020, 12 (03):
  • [3] Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury
    Artham, Sandeep
    Gao, Fei
    Verma, Arti
    Alwhaibi, Abdulrahman
    Sabbineni, Harika
    Hafez, Sherif
    Ergul, Adviye
    Somanath, Payaningal R.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 141 : 249 - 263
  • [4] Hsp90 inhibitors suppress P53 phosphorylation in LPS - induced endothelial inflammation
    Barabutis, Nektarios
    Uddin, Mohammad A.
    Catravas, John D.
    [J]. CYTOKINE, 2019, 113 : 427 - 432
  • [5] Regulation of pulmonary endothelial barrier function by kinases
    Barabutis, Nektarios
    Verin, Alexander
    Catravas, John D.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2016, 311 (05) : L832 - L845
  • [6] TRAF1 meditates lipopolysaccharide-induced acute lung injury by up regulating JNK activation
    Bin, Wan
    Ming, Xue
    Wen-Xia, Chen
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 511 (01) : 49 - 56
  • [7] Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978-1-4939-7000-1_26
  • [8] Cai XD, 2019, AM J TRANSL RES, V11, P1884
  • [9] Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
  • [10] Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations
    Cao, Yanan
    Li, Lin
    Feng, Zhimin
    Wan, Shengqing
    Huang, Peide
    Sun, Xiaohui
    Wen, Fang
    Huang, Xuanlin
    Ning, Guang
    Wang, Weiqing
    [J]. CELL DISCOVERY, 2020, 6 (01)